Download PDF
Arzneimittelforschung 2012; 62(02): 88-93
DOI: 10.1055/s-0031-1295487
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Contribution of Formulation and Excipients Towards Enhanced Permeation of Curcumin

B. Wahlang
1   Department of Pharmaceutics, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India
,
D. Kabra
2   Laboratory of Chromatin Biology, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India
3   Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio, U.S.A.
,
Y. B. Pawar
1   Department of Pharmaceutics, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India
,
K. Tikoo
2   Laboratory of Chromatin Biology, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India
,
A. K. Bansal
1   Department of Pharmaceutics, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India
› Author Affiliations
Further Information

Publication History

received 13 October 2011

accepted 09 November 2011

Publication Date:
16 February 2012 (online)

    Permissions and Reprints

Abstract

Curcumin (CRM) (CAS number 458-37-07), a naturally-occurring molecule, has diverse pharmacological actions. Recently our research group demonstrated that poor permeability also contributes to its poor oral bioavailability. A self nano-emulsifying drug delivery system (CRM SNEDDS) consisting of Labrasol, Gelucire 44/14, Vitamin E TPGS and PEG 400 was designed and provided 16 times improvement in oral bioavailability in rats, at a dose of 250 mg/kg body weight. Caco-2 cell transport studies were conducted for CRM SNEDDS and CRM in the presence of individual excipients, to determine the extent of improvement in permeability. Papp values for CRM, CRM SNEDDS and CRM in combination with 4 individual excipients were calculated. Transepithelial electrical resistance value was assessed to evaluate the cell morphology and the cellular tight junctions. Permeation of a transcellular marker, Lucifer Yellow was used as a marker to assess monolayer integrity. The tested excipient concentrations were found to be non-toxic to the cell monolayer in 2 h incubation. Results showed that the Papp increased 6.35 times for curcumin in CRM SNEDDS as compared to CRM. Individual excipients enhanced permeation from 1.97 to 6.35 times, with Labrasol showing the highest enhancement of 6.35 times.

Key words

curcumin - oral bioavailability - permeability
 

  • References

  • 1 Maheshwari RK, Singh AK, Gaddipati J et al. Multiple biological activities of curcumin: A short review. Life Sci 2006; 78: 2081-2087
    CrossrefPubMedGoogle Scholar
  • 2 Kawamori T, Lubet R, Steele VE et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999; 59: 597-601
    PubMedGoogle Scholar
  • 3 Sharma S, Kulkarni SK, Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006; 33: 940-945
    CrossrefPubMedGoogle Scholar
  • 4 Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol 2007; 595: 197-212
    PubMedGoogle Scholar
  • 5 Wang Q, Sun AY, Simonyi A et al. Neuroprotective mechanisms of curcumin against cerebral ischemia-induced neuronal apoptosis and behavioral deficits. J Neurosci Res 2005; 82: 138-148
    CrossrefPubMedGoogle Scholar
  • 6 Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363-398
    PubMedGoogle Scholar
  • 7 Gao X, Kuo J, Jiang H et al. Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. Biochem Pharmacol 2004; 68: 51-61
    CrossrefPubMedGoogle Scholar
  • 8 Varalakshmi C, Ali AM, Pardhasaradhi BVV et al. Immunomodulatory effects of curcumin: In-vivo. Int Immunopharmacol 2008; 8: 688-700
    CrossrefPubMedGoogle Scholar
  • 9 Tonnesen HH, Masson M, Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm 2002; 244: 127-135
    CrossrefPubMedGoogle Scholar
  • 10 Wang Y-J, Pan M-H, Cheng A-L et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1996; 15: 1867-1876
    PubMedGoogle Scholar
  • 11 Garcea G, Jones DJ, Singh R et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004; 90: 1011-1015
    CrossrefPubMedGoogle Scholar
  • 12 Sou K, Inenaga S, Takeoka S et al. Loading of curcumin into macrophages using lipid-based nanoparticles. Int J Pharm 2008; 352: 287-293
    CrossrefPubMedGoogle Scholar
  • 13 Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 2007; 337: 299-306
    CrossrefPubMedGoogle Scholar
  • 14 Bisht S, Feldmann G, Soni S et al. Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): a novel strategy for human cancer therapy. J Nanobiotechnology 2007; 5: 3
    CrossrefPubMedGoogle Scholar
  • 15 Paradkar A, Ambike AA, Jadhav BK et al. Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int J Pharm 2004; 271: 281-286
    CrossrefPubMedGoogle Scholar
  • 16 Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005; 104: 1322-1331
    CrossrefPubMedGoogle Scholar
  • 17 Kumar V, Lewis SA, Mutalik S et al. Biodegradable microspheres of curcumin for treatment of inflammation. Indian J Physiol Pharmacol 2002; 46: 209-217
    PubMedGoogle Scholar
  • 18 Gershanik T, Benzeno S, Benita S. Interaction of a self-emulsifying lipid drug delivery system with the everted rat intestinal mucosa as a function of droplet size and surface charge. Pharm Res 1998; 15: 863-869
    CrossrefPubMedGoogle Scholar
  • 19 Wang Z, Sun J, Wang Y et al. Solid self-emulsifying nitrendipine pellets: preparation and in vitro/in vivo evaluation. Int J Pharm 383: 1-6
    PubMedGoogle Scholar
  • 20 Buyukozturk F, Benneyan JC, Carrier RL. Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics. J Control Release 2010; 142: 22-30
    CrossrefPubMedGoogle Scholar
  • 21 Volpe DA, Faustino PJ, Ciavarella AB et al. Classification of Drug Permeability with a Caco-2 Cell Monolayer Assay. Clinical Research and Regulatory Affairs 2007; 24: 39-47
    CrossrefPubMedGoogle Scholar
  • 22 Hou X-L, Takahashi K, Kinoshita N et al. Possible inhibitory mechanism of Curcuma drugs on CYP3A4 in 1[alpha], 25 dihydroxyvitamin D3 treated Caco-2 cells. Int J Pharm 2007; 337: 169-177
    CrossrefPubMedGoogle Scholar
  • 23 Wahlang B, Pawar YB, Bansal AK. Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. Eur J Pharm Biopharm 2010; In Press
    PubMedGoogle Scholar
  • 24 Schmiedlin-Ren P, Thummel KE, Fisher JM et al. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol Pharmacol 1997; 51: 741-754
    PubMedGoogle Scholar
  • 25 Fisher JM, Wrighton SA, Watkins PB et al. First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. J Pharmacol Exp Ther 1999; 289: 1134-1142
    PubMedGoogle Scholar
  • 26 Koga K, Kawashima S, Murakami M. In vitro and in situ evidence for the contribution of Labrasol and Gelucire 44/14 on transport of cephalexin and cefoperazone by rat intestine. Eur J Pharm Biopharm 2002; 54: 311-318
    CrossrefPubMedGoogle Scholar
  • 27 Sachs-Barrable K, Lee S, Thamboo A et al. Influence of the lipid excipient, Gelucire 44/14, on P-glycoprotein (P-gp) activity in an intestinal endothelial cell line (Caco-2) www.aapsj.org/abstracts/AM_2006/staged/AAPS2006-000193
    PubMed
  • 28 Chang T, Benet LZ, Hebert MF. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1996; 59: 297-303
    CrossrefPubMedGoogle Scholar
  • 29 Yu L, Bridgers A, Polli J et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 1999; 16: 1812-1817
    CrossrefPubMedGoogle Scholar
  • 30 Brown JR, Collett JH, Attwood D et al. Influence of monocaprin on the permeability of a diacidic drug BTA-243 across Caco-2 cell monolayers and everted gut sacs. Int J Pharm 2002; 245: 133-142
    CrossrefPubMedGoogle Scholar